SCHEMBL2194579

SCHEMBL2194579

Fc1ccc(CN(I)I)cc1.[Pt]=c1n(Cc2ccccc2)ccn1Cc1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 1/20 0.41
MAPT P10636 1/20 0.41
THRB P10828 1/20 0.41
KDM4E B2RXH2 3/20 0.41
ALDH1A1 P00352 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
CYP11B1 P15538 1/20 0.40
CYP11B2 P19099 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
GAA P10253 2/20 0.38
LMNA P02545 3/20 0.38
HPGD P15428 1/20 0.38
KCNA5 P22460 1/20 0.38
BCHE P06276 1/20 0.37
ACHE P22303 1/20 0.37
BACE1 P56817 1/20 0.37
DBH P09172 1/20 0.37
CYP19A1 P11511 1/20 0.36
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2197402 0.91 ALDH1A1 (0.40) MAPTKDM4EALDH1A1L3MBTL1CYP11B1
SCHEMBL2193549 0.87 SIGMAR1 (0.42) MAPTTHRBKDM4EALDH1A1CYP11B1
SCHEMBL2195700 0.86 MAPT (0.45) MAPTTHRBKDM4EALDH1A1CYP11B1
SCHEMBL2191713 0.86 CYP11B1 (0.40) MAPTKDM4EALDH1A1L3MBTL1CYP11B1
SCHEMBL2196798 0.85 BCHE (0.41) MAPTKDM4EALDH1A1SMN1; SMN2GAA
SCHEMBL2195793 0.80 LMNA (0.42) MAPTKDM4EALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL2193860 0.77 KDM4E (0.36) MAPTTHRBKDM4EALDH1A1SMN1; SMN2
SCHEMBL2193843 0.77 MET (0.43) MAPTKDM4EALDH1A1SMN1; SMN2GAA
SCHEMBL2193845 0.77 POLB (0.39) MAPTKDM4EALDH1A1SMN1; SMN2GAA
SCHEMBL2194976 0.76 SIGMAR1 (0.44) MAPTL3MBTL1CYP11B1CYP11B2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8980875-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2015-03-17 US claimed
US-20130338128-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-12-19 US claimed
US-8481522-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-07-09 US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130338128-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 CNR2 203/4885MAPT 4712/4885THRB 1005/4885
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 CNR2 203/4885MAPT 4712/4885THRB 1005/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.